Synthetic Human Papillomavirus 16 E6 Peptide(Nci)(Synthetic Human Papillomavirus 16 E6 Peptide(Nci))

概要

基本信息

药物类型

通用抗原疫苗、合成肽疫苗、治疗性疫苗

别名

synthetic human papillomavirus 16 E6 peptide(NCI)

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤消化系统疾病泌尿生殖系统疾病+ [1]

在研适应症-

非在研适应症

肛门肿瘤食管癌局部晚期宫颈癌+ [4]

原研机构

National Cancer Institute

在研机构-

非在研机构

National Cancer Institute

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Synthetic Human Papillomavirus 16 E6 Peptide(Nci) 相关的临床试验

NCT00002916 / Completed临床2期IIT

A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins

RATIONALE: Vaccines made from human papillomavirus may make the body build an immune response to and kill cervical cancer cells. Combining vaccine therapy with surgery may be a more effective treatment for cervical cancer.
PURPOSE: This phase II trial is studying how well giving vaccine therapy together with surgery works in treating patients with early cervical cancer.

开始日期1996-11-01

申办/合作机构

Eortc

NCT00019110 / Completed临床1期IIT

VACCINE THERAPY AND DETECTION OF IMMUNOLOGIC RESPONSES WITH HUMAN PAPILLOMAVIRUS 16 E6 AND E7 PEPTIDES IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED CERVICAL CANCER

RATIONALE: Vaccines made from certain human papillomaviruses may be able to help the body to kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of human papillomavirus vaccine therapy in treating patients who have advanced or recurrent cancer of the cervix, vagina, penis, anus, esophagus, or head and neck.

开始日期1995-11-01

申办/合作机构

National Cancer Institute

100 项与 Synthetic Human Papillomavirus 16 E6 Peptide(Nci) 相关的临床结果

登录后查看更多信息

100 项与 Synthetic Human Papillomavirus 16 E6 Peptide(Nci) 相关的转化医学

登录后查看更多信息

100 项与 Synthetic Human Papillomavirus 16 E6 Peptide(Nci) 相关的专利（医药）

登录后查看更多信息

8

项与 Synthetic Human Papillomavirus 16 E6 Peptide(Nci) 相关的文献（医药）

2024-01-02·Journal of Biomolecular Structure and Dynamics

Fragment-based design and MD simulations of human papilloma virus-16 E6 protein inhibitors

Review

作者: Marudamuthu, Amarnath Satheesh ; Prasad, Sanjay ; Seal, Priyanka ; B M, Suman ; Vemula, Vani ; Alagumuthu, Manikandan ; S E, Mamatha ; A, Swathi

The main objective of this study is to screen potential small molecule inhibitors against HPV (Human Papilloma Virus)-16 E6 protein (HPV16 E6P) using a fragment-based approach. Twenty-six natural HPV inhibitors were selected based on the review of the literature. Among them, Luteolin was selected as the reference compound. These 26 compounds were used to generate novel inhibitors against HPV16 E6P. Fragment script and BREED of Schrodinger software were used to build novel inhibitor molecules. The result in 817 novel molecules was docked into the active binding site of HPV E6 protein and the top ten compounds were screened based on binding affinity compared to Luteolin for further study. Compounds Cpd5, Cpd7, and Cpd10 were the most potent inhibitors of HPV16 E6P and these were non-toxic and showed high Gastrointestinal (GI) absorption and positive drug-likeness score. Complexes of these compounds were stable in the 200 ns Molecular Dynamics (MD) simulation. These 3 HPV16 E6P inhibitors could be the lead molecules as new drugs for HPV-related diseases.Communicated by Ramaswamy H. Sarma.

2021-01-01·International Immunopharmacology2区 · 医学

Anti-pulmonary metastases from cervical cancer responses induced by a human papillomavirus peptide vaccine adjuvanted with CpG-oligodeoxynucleotides in vivo

2区 · 医学

Article

作者: Che, Yuxin ; Lv, Xueying ; Suo, Jinguo ; Yang, Yang ; Chen, Chunyan ; Wang, Xuelian

Metastasis, particularly hematogenous metastasis, is associated with poor prognosis in patients with cervical cancer. The lungs are the most common site for hematogenous metastasis of cervical cancer. The currently available therapeutic modalities, including surgery, radiotherapy, or chemotherapy do not provide satisfactory clinical outcome for patients with pulmonary metastases. Therefore, it is necessary to investigate an alternative efficacious treatment modality. Therapeutic vaccines may evoke tumor-specific immune responses in patients to attack tumor cells, representing an attractive treatment option for controlling metastatic tumors. Our previous study demonstrated that a single administration of a human papillomavirus 16 E7 peptide vaccine, adjuvanted with unmethylated CpG-oligodeoxynucleotides, induced the clearance of subcutaneous xenograft cervical cancer. In this study, we investigated the anti-metastases responses induced by this vaccine using a murine model of pulmonary metastases from cervical cancer. The results showed that subcutaneous administration of the vaccine inhibited the growth of pulmonary metastases, which may be attributed to the increased infiltration of CD4 + and CD8 + T cells, and decreased number of immunosuppressive cells (including myeloid-derived suppressive cells and tumor-associated macrophages) in the lungs. Meanwhile, the alteration in a panel of cytokines, chemokines, and matrix metalloproteinases induced by the vaccination may contribute to the re-modulation of the local suppressive environment and inhibition of pulmonary metastases. To the best of our knowledge, this is the first report on the efficacy of the vaccine formula against murine pulmonary metastases from cervical cancer.

2019-12-01·Molecular Therapy - Methods & Clinical Development2区 · 医学

Phase 1 Safety and Immunogenicity Trial of Recombinant Lactococcus lactis Expressing Human Papillomavirus Type 16 E6 Oncoprotein Vaccine

2区 · 医学

ArticleOA

作者: Mohseni, Amir Hossein ; Keyvani, Hossein ; Taghinezhad-S, Sedigheh ; Razavi, Mohammad Reza

The present study purposed to investigate the safety, tolerability, and immunogenicity of the therapeutic NZ8123-HPV16-optiE6 vaccine, following oral vaccination. The safety and tolerability were evaluated. Specific serum immunoglobulin G (IgG) and vaginal IgA antibodies were calculated by ELISA, and E6-specific IFN-γ-secreting T cells were counted by enzyme-linked immune absorbent spot (ELISpot) assay in cervical lymphocytes and PBMC samples. The vaccine was well tolerated, and no serious adverse effects were observed in vaccine recipients. Statistical analysis showed that all vaccine groups had significant increases in antibody levels at day 60 after baseline. The time to peak activation in E6-specific IFN-γ-secreting CD8⁺ CTL responses was seen at month 1 after last vaccination. According to the results, the humoral immune and cell-mediated responses for the vaccine groups that received 5 × 10⁹ and 1 × 10¹⁰ CFU/mL of vaccine were similar and were higher than those of the 1 × 10⁹ CFU/mL group, indicating the dose-dependency of the NZ8123-HPV16-optiE6 vaccine following oral administration. Low antibody levels compared with the placebo groups were recorded at month 6 after the last vaccination. Interestingly, long-term E6-specific CTL responses were observed during follow-up. It was concluded that oral immunization with the NZ8123-HPV-16-optiE6 vaccine is safe, induces persistent immunity, and is reasonably well tolerated.

100 项与 Synthetic Human Papillomavirus 16 E6 Peptide(Nci) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肛门肿瘤	临床1期	美国	National Cancer Institute	1995-11-01
食管癌	临床1期	美国	National Cancer Institute	1995-11-01
局部晚期宫颈癌	临床1期	美国	National Cancer Institute	1995-11-01
转移性宫颈癌	临床1期	美国	National Cancer Institute	1995-11-01
阴茎肿瘤	临床1期	美国	National Cancer Institute	1995-11-01
复发癌	临床1期	美国	National Cancer Institute	1995-11-01
外阴肿瘤	临床1期	美国	National Cancer Institute	1995-11-01